Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Brief description of study

This study is designed for patients diagnosed with advanced solid tumors and is testing a novel epigenetic modifying strategy to restore tumor cell differentiation.

The study will evaluate safety, tolerability, and pharmacokinetics of NUV-868, a BD-2 selective inhibitor of BRD4 as monotherapy and in combination with olaparib or enzalutamide and evaluate antitumor activity in advanced solid tumors.


Clinical Study Identifier: s22-01098
Principal Investigator: David R. Wise.
Other Investigators: Daniel J Becker, Victor Ricardo Adorno Febles, Minas Platon Economides, Kristen Spencer, Scot Niglio, Keriann M Scavone, Nina Beri, Jennifer Chuy, Paul E. Oberstein, Rafael Winograd, Shun Yu, Hank Ng.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.